Dosimetry-Driven Alpha Emitter Selection for Radioligand Therapy: A Real World Application comparing 225 Ac with 212 Pb
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The selection of a radionuclide is critical for optimizing radioligand therapy (RLT). The choice of alpha-emitter should take into account the pharmacokinetics of the radioligand. We aimed to model and compare the dosimetry and therapeutic index (TI) of a single pharmaceutical, rhPSMA-10.1, when labeled with either 225 Ac or 212 Pb, using human pharmacokinetic data.
METHODS
Dosimetry data from a Phase 1 trial of 177 Lu-rhPSMA-10.1 in 13 mCRPC patients was used to generate time–activity curves for tumors and organs-at-risk (kidneys, salivary glands). These curves were used to model the dosimetry of 225 Ac-rhPSMA-10.1 and 212 Pb-rhPSMA-10.1 by substituting the physical half-life and decay properties of 177 Lu with those of the alpha-emitters. Absorbed doses and TIs were calculated. The potential impact of daughter radionuclide translocation on organ doses and TIs was also modeled.
RESULTS
To deliver a 5Gy (RBE5) absorbed dose to tumors, a ~29-fold higher administered activity of 212 Pb was required compared to 225 Ac (mean 131 MBq versus 4.6 MBq, respectively). At this tumor dose, the required activity of 212 Pb resulted in 2.5-fold and 2.2-fold higher absorbed doses to the kidneys and salivary glands, respectively, compared with 225 Ac. Consequently, 225 Ac demonstrated a substantially improved TI, with a ~3-fold higher tumor:kidney dose ratio (9.85 versus 3.36) and a ~2.2-fold higher tumor:salivary gland ratio (15.9 versus. 7.1). Even when modeling a conservative worst-case scenario for daughter translocation, 225 Ac maintained a superior TI. Importantly, based on the pharmacokinetics of this drug, to achieve 120Gy (RBE5) absorbed dose to tumors would require the delivery of 12.1Gy (RBE5) and 35.7Gy (RBE5) to the kidneys for 225 Ac and 212 Pb respectively. When daughter translocation is modelled, these values are 39.1Gy (RBE5) and 114.3Gy (RBE5) respectively.
CONCLUSIONS
The physical half-life of 225 Ac is better suited to the pharmacokinetic profile of rhPSMA-10.1 than the shorter half-life of 212 Pb. This results in a substantially enhanced TI for 225 Ac-rhPSMA-10.1, permitting the delivery of markedly lower absorbed doses to organs-at-risk for a fixed tumor dose. This work highlights the critical importance of matching radionuclide half-life with drug pharmacokinetics to optimize RLT.
